Phase 1/2Completed
Senolytic Therapy to Modulate Progression of Alzheimer's Disease (SToMP-AD)
Pilot Study to Investigate the Safety and Feasibility of Senolytic Therapy to Modulate Progression of Alzheimer's Disease (SToMP-AD)
- Sponsor
- The University of Texas Health Science Center at San Antonio (Academic or other)
- Enrolment
- 5 enrolled
- Conditions
- Alzheimer Disease
- Interventions
- Dasatinib + Quercetin
- Ages
- older adults
- Registry
- NCT04063124
From the registry
The purpose of this pilot study is to evaluate whether a combination of two drugs, dasatinib (D) and quercetin (Q) \[D+Q\], penetrate the brain using cerebrospinal fluid (CSF) in older adults with early Alzheimer's disease (AD). This combination of drug therapy has been shown to affect dying cells in humans with other chronic illnesses and in Alzheimer's mice models. The study team want to know if this combination of medications will reach the brain in order to evaluate if this intervention may be effective for treating AD symptoms in future studies. This is also known as a "proof of concept" study.
Primary outcomes
- Brain Penetrance of Dasatinib (D)
- Brain Penetrance of Quercetin (Q)